Table 2. Clinicopathologic features of the four groups.
| Clinicopathologic features | Group 1 (n=45) |
Group 2 (n=40) |
Group 3 (n=174) |
Group 4 (n=39) |
Univariate Analysis | |
|---|---|---|---|---|---|---|
| F/χ2/H | P value | |||||
| Sex, n (%) | ||||||
| Male | 7(15.6) | 4(10.0) | 71(40.8) | 11(28.2) | 21.144 | 0.000* |
| Female | 38(84.4) | 36(90.0) | 103(59.2) | 28(71.8) | ||
| Age (years) | ||||||
| Mean ± SD | 38.36±13.35 | 33.38±10.46 | 41.76±10.91 | 36.38+10.51 | 7.516 | 0.000* |
| Tumor size (cm) | ||||||
| Median (range) | 1.0(0.6-1.5) | 1.4(0.7-2.2) | 1.0(0.7-1.5) | 0.9(0.5-1.5) | 7.121 | 0.068 |
| Tumor multifocality, n (%) | ||||||
| No | 19(42.2) | 18(45.0) | 77(44.3) | 17(43.6) | 0.081 | 0.994 |
| Yes | 26(57.8) | 22(55.0) | 97(55.7) | 22(56.4) | ||
| Tumor lesion, n (%) | ||||||
| Unilateral | 33(73.3) | 32(80.0) | 106(60.9) | 23(59.0) | 7.234 | 0.065 |
| Bilateral | 12(26.7) | 8(20.0) | 68(39.1) | 16(41.0) | ||
| Extracapsular invasiveness, n (%) | ||||||
| No | 18(40.0) | 24((60.0) | 69(39.7) | 20(51.3) | 6.622 | 0.085 |
| Yes | 27(60.0) | 16(40.0) | 105(60.3) | 19(48.7) | ||
| TNM-Stage, n (%) | ||||||
| I | 28(62.2) | 32(80.0) | 103(59.2) | 32(82.1) | 12.976 | 0.164 |
| II | 0(0) | 0(0) | 2(1.1) | 0(0) | ||
| III | 8(17.8) | 4(10.0) | 28(16.1) | 3(7.7) | ||
| IV | 9(20.0) | 4(10.0) | 41(23.6) | 4(10.3) | ||
| 131I dose | ||||||
| Median (range) | 100(30-150) | 60(30-150) | 30(30-150) | 30(30-30) | 21.293 | 0.000* |
| Ps-Tg level (ng/mL) | ||||||
| Median (range) | 0.1(0.1-1.5) | 0.3(0.1-1.9) | 2.1(0.6-7.0) | 1.9(0.7-6.3) | 35.987 | 0.000* |
| Ps-TSH level (μIU/mL) | ||||||
| Median (range) | 100.0(73.2-138.4) | 130.5(86.5-150.0) | 100.0(75.7-129.3) | 103.3(75.3-137.5) | 6.520 | 0.089 |
*P<0.05; Ps-Tg, preablative-stimulated thyroglobulin; Ps-TSH: preablative thyroid stimulating hormone.